healing. These results reveal that W9 has an effect on fractures of promoting healing and could be applied as a fracture treatment.
Introduction
Bone formation is regulated by cytokines and factors such as bone morphogenetic proteins (BMPs) [1] , parathyroid hormone (PTH) [2] , statins [3] , Wingless-type (Wnt) [4] , growth hormone [5] , and insulin-like growth factor (IGF)-1 [6] , which induce differentiation and mineralization of osteoblasts. These factors are candidates for pharmaceuticals with bone anabolic activity, but at this stage, PTH is the only clinically available bone anabolic drug. The major difficulty in the development of such drugs is the lack of clarification of the mechanisms regulating osteoblast differentiation and bone formation. In addition, nonunion is a serious problem when fractures are treated clinically. No alternative treatment other than the use of a PTH preparation or low-intensity pulsed ultrasound is readily available. Consequently, novel treatments that promote bone anabolic factors, and are easy to use and widely available, are needed for the treatment of fractures, especially in cases of nonunion.
WP9QY peptide (W9) consists of nine amino acids. W9 was originally designed to mimic a critical binding site of tumor necrosis factor (TNF)-α on the TNF type 1 receptor in a small molecular agent development stream [7] . Subsequently, W9 has been proven to work as a RANKL antagonist as well as a TNF-α antagonist [8] . W9 blocks RANKL-induced osteoclastogenesis and then blocks bone Abstract The WP9QY peptide (W9) consists of nine amino acids. It binds to RANKL and blocks RANKLinduced increases in bone resorption and osteoclastogenesis. W9 has a unique effect on the coupling mechanism between osteoclasts and osteoblasts, which promotes bone formation while working to suppress bone resorption. In this study, with the aim of clinical application of W9 for fracture treatment, we aimed to clarify the bone repair-promoting effect of W9 when administered locally to a rat femur model of delayed union. Using SpragueDawley rats, a model of delayed union was created in the right femur by cauterizing the periosteum. Injection of W9 (1 mg in 100 μl) or phosphate-buffered saline (PBS) (100 μl) at the fracture site was performed at the operation and every week thereafter until death (sacrifice). The bone union rate was 14% in the PBS group and 57% in the W9 group at 8 weeks postoperatively. The X-ray score of the W9 group was significantly higher than that of the PBS group at 8 weeks postoperatively. When bone morphometry was analyzed by micro-computed tomography (CT), total callus volume (TV) and mineralized callus bone volume (BV) were measured. TV showed no significant difference between the two groups, but BV/TV was significantly higher in the W9 group. This finding suggests that local administration of W9 can promote bone maturation from callus and can be considered to contribute to fracture 1 3 resorption activity by connecting to RANKL. In addition, Furuya et al. recently reported the stimulatory effects of W9 on bone formation [9] . Subcutaneous injections of W9 increased both the bone mineral density and the mineral apposition rate of the femur in mice.
Peptide-based therapeutics is one of the fastest growing classes of new drugs [10] . Peptides, being short polymers typically less than 50 amino acids in length and less than 10 kDa in molecular weight [11, 12] , have unique advantages as therapeutic agents. Peptides are small in molecular size compared to large macromolecules (>100 kDa) such as antibodies, and are promising candidates for developing therapeutic drugs with fewer side effects, particularly because large macromolecules have clear disadvantages, including poor bioavailability, production of neutralizing antibodies, expense, and risk of severe and occasionally life-compromising side effects.
In this study, with the aim of clinical application of W9 for fracture treatment, we aimed to clarify the bone repairpromoting effect of W9 following local administration to the rat femur in a delayed-union model.
Materials and methods

Peptides
Peptides [WP9QY (W9); YCWSQYLCY] (10 mg/ml) were synthesized by the fluorenylmethoxycarbonyl method and formed a disulfide link [7] . These peptide solutions were prepared by Oriental Yeast Co.
Animal models
This study was approved by the Ethics Committee for Experimental Animals of Hiroshima University. All animals were treated according to the guidelines stipulated by the Institutional Animal Care and Use Committee.
Male Sprague-Dawley (SD) rats, 12 weeks of age, with a mean weight of 360 g (range, 340-370 g) were used throughout the study. Rats were obtained from Charles River Laboratories Japan (Yokohama, Japan).
Under sterile conditions, animals were anesthetized by intraperitoneal administration of sodium 5-ethyl-5-barbiturate (50 mg/kg). Nonunion was induced in the right femur by cauterizing the periosteum as previously described [13] . A lateral parapatellar incision on the right limb was made to expose the distal femoral condyle. To avoid significant fracture displacement while obtaining well-aligned stability of the fracture, a 1.2-mm-diameter Kirschner wire was inserted from the trochlear groove into the femoral canal in a retrograde manner. A thin saw cut to a depth of 3 mm was made in the mid-shaft after minimal lateral exposure to weaken the bone and to avoid complex fractures. A transverse femoral shaft fracture was then produced using a C-shaped instrument by applying three-point bending. After this procedure, the periosteum was cauterized circumferentially at a distance of 2 mm on each side of the fracture to produce nonunion. Then, local injection of W9 (1 mg in 100 µl) or phosphate-buffered saline (PBS) (100 µl) was administered at the fracture site. Finally, the wound was closed in layers, and W9 (1 mg in 100 µl) or PBS (100 µl) was injected at the fracture site every week until death by sacrifice. Because there are no reports about local injection of W9, the concentration of W9 (1 mg in 100 µl) was determined by a subcutaneous model of the previous study [9] , which showed ectopic bone formation about collagen sponges soaked with BMP-2 implanted in the dorsal fascia of normal mice, and subcutaneous administration of W9 (5 mg/kg) to the mice increased the bone mineral content of collagen sponges.
Radiologic evaluation
Radiographs of all rats were obtained following creation of the fracture and at 2-week intervals until the time of death, carried out under anesthesia with the animal prone and with both limbs fully abducted. Fracture union was determined by the presence of bridging callus on two cortices. Radiographs of each animal were assessed under a triple-blinded protocol by means of a scoring scale that was based on rebridging of the cortices and acceleration of healing [14] .
Micro-computed tomography analysis
In preparation for the micro-computed tomography (µCT) analysis, the Kirschner wires were removed from the femoral canal. μCT determination of the excised bones was performed using a Sky Scan 1176 μCT scanner (Bruker MicroCT, Kontich, Belgium). Bones were cleaned of soft tissue, and the scanning procedure was initially conducted using the following settings: 40 kVp, fixed µA; 100; and no filter, at an isotropic resolution of 18 µm. The acquisition consisted of the realization of several two-dimensional (2D) lateral projections of the phantom during a 360° rotation around the vertical axis. In total, 286 micro-tomographic slices were acquired with an 18-µm-slice increment covering a total range of 10 mm (encompassing 5 mm proximal and distal to the fracture line). The scanned zone included the original cortical diaphyseal bone as well as the entire periosteal and endosteal callus. Reconstruction was carried out using a modified Feldkamp 188 algorithm using Sky Scan Nrecon software (Bruker MicroCT). Axial slices of the callus 5 mm proximal and distal to the fracture line were manually contoured for segmentation to define the periosteal surface and exclude the original cortical bone using CT analyzer software. A value of 351 mg HA/mm 3 was used to distinguish mineralized tissue [mineralized callus volume (BV, mm
3 )] from poorly mineralized and unmineralized tissue [15] . Microarchitectural parameters including total callus volume (TV, mm 3 ) and BV/TV [16, 17] were calculated.
Histological evaluation by toluidine blue staining
Specimens were fixed in 10% paraformaldehyde, decalcified with 10% EDTA solution, pH 7.4, for 4 weeks, and embedded in paraffin. Sagittal sections (5 mm thick) from each sample were prepared, stained with toluidine blue, and examined under a light microscope (Olympus, Tokyo, Japan).
TRAP staining and osteoclast quantification
Tissue sections, prepared by the same method as for toluidine blue staining, were stained with tartrate-resistant acid phosphatase (TRAP) using a TRAP/alkaline phosphatase (ALP) stain kit (Wako, Osaka, Japan). After staining, the numbers of multinucleated (≥3 nuclei) TRAP+ osteoclasts were analyzed in a 1600 µm (height) × 2800 µm (width) area centered in the middle of the fracture callus. The number and size of TRAP+ osteoclasts were measured using BioQuant Osteo software (v. 12.5.60; BIOQUANT Image Analysis, Nashville, TN, USA).
Villanueva bone staining and osteoblast quantification
After the removal of soft tissues, the right femurs were subjected to Villanueva bone staining for 7 days without decalcifying treatment [18] , dehydrated with increasing concentrations of ethanol, and embedded in methyl methacrylate (Wako Pure Chemical). Sagittal sections of the femur (5 μm thick) were prepared using a microtome (Leica, Wetzlar, Germany). Osteoblast numbers were analyzed in an area 1600 µm (in height) × 2800 µm (in width) centered in the middle of the fracture callus. The number of osteoblasts was counted using BioQuant Osteo software (v. 12.5.60; BIOQUANT).
Reverse transcription polymerase chain reaction (PCR) and quantitative real-time PCR
Total RNA was obtained from the rat callus in the peri-fracture site at day 14 using Trizol (Invitrogen; Thermo Fisher Scientific, Waltham, MA, USA) according to the manufacturer's instructions. To examine the gene expression of connective tissue growth factor (CTGF), Col1A1, osteocalcin, bone morphogenetic protein 4 (BMP4), insulin-like growth factor 1 (IGF1), F-mod, and ALP1, real-time PCR was performed using a TaqMan assay kit (Applied Biosystems, Foster City, CA, USA). Total RNA was isolated with Trizol reagent (Thermo Fisher), total RNA yields were calculated, and quality was determined using absorption spectroscopic analysis. cDNA was synthesized using 2 µg total RNA with a Superscript VILO kit (Invitrogen; Thermo Fisher) according to the manufacturer's protocol. Realtime PCR was performed using TaqMan Gene Expression Assay probes (Life Technologies; Thermo Fisher) for CTGF (Rn01537279_g1), Col1A1 (Rn01463848_m1), osteocalcin (Rn00566386_g1), BMP4 (Rn00432087_m1), IGF1 (Rn00710306_m1), F-mod (Rn00589918_m1), ALP1 (Rn01516028_m1), and GAPDH (Rn01775763_g1). The GAPDH gene was used as a control to normalize differences in total RNA levels in each sample. A threshold cycle (CT) was observed in the exponential phase of amplification, and quantification of relative expression levels was performed using standard curves for target genes and the endogenous control. Geometric means were used to calculate the ΔΔC T (delta-delta C T ) values and expressed as 2 − C T . The value of each control sample was set at 1, and the biological duplicate of each sample was averaged to calculate the fold change of target genes.
Statistical analysis
All data are expressed as mean ± standard deviation (SD). Differences in the amount of bone formation and mineralization, cartilage formation, and fibrous tissue formation between the PBS group and W9 group were determined using either an independent-group t test or a Mann-Whitney U test, depending on normality, determined by a Shapiro-Wilk test. Analyses were performed using standard statistical software (SAS 9.1; SAS Institute, Cary, NC, USA). A P value <0.05 was considered as significant.
Results
Fracture union was determined by the presence of bridging callus on two cortices on an X-ray image. The bone union rate was 14% in the PBS group and 57% in the W9 group at postoperative week 8 (Figs. 1, 2a) . Bone formation in X-ray images was assessed using a radiographic score [14] as described in "Radiologic evaluation." At all time points analyzed, the average radiographic sore was higher in the W9 group. Especially, the score of the W9 group was significantly higher than that of the PBS group at 8 weeks postoperatively (P < 0.05; Fig. 2b ).
When bone morphometry was analyzed by micro-CT at week 8, TV and BV were measured. On average, TV was a little higher in the W9 group, but there was no significant difference between the two groups. On the other hand,
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BV/TV was significantly higher in the W9 group (P < 0.05; Fig. 3 ).
Histological evaluation using toluidine blue staining demonstrated enhanced endochondral ossification, consisting of numerous chondrocytes and newly formed woven bone at week 4 and bridging callus formation at weeks 6 and 8 in the W9 group. On the other hand, at postoperative week 8, a fibrous tissue intervened around a callus in three of seven cases that showed nonunion. In the PBS group, although newly formed woven bone was observed to some extent at week 4, fracture gaps were not filled with bridging callus at week 8. In the PBS group, most of the fracture site was filled with fibrous tissue (Fig. 4) .
The number of TRAP+ osteoclasts was quantified in the fracture callus of the PBS group and the W9 group at postoperative weeks 4, 6, and 8. At all time points, there was a significant decrease in the number of osteoclasts in the W9 group compared with the PBS group (P < 0.05; Fig. 5 ).
The number of osteoblasts was counted using Villanueva bone staining at 4 weeks postoperatively. The number of osteoblasts in the fracture callus was significantly higher in the W9 group than in the PBS group (P < 0.05; Fig. 6 ).
The expression levels of CTGF, Col1A1, osteocalcin, BMP4, and ALP1 in the callus of the peri-fracture site were significantly higher in the W9 group compared with the PBS group (P < 0.05; Fig. 7 ).
Discussion
This is the first report to show that local injection of W9 peptide into a fracture site promotes fracture healing. Simply, W9 consists of nine amino acids without cells, so handling is simple and easy. W9 has the potential to promote fracture healing, so it will be suitable for application in human bone fracture treatment. The most frequently used operation for nonunion has been autogenous bone grafting, such as conventional bone grafting from the ilium and free vascularized bone grafting [19, 20] , which require harvesting of bones from intact sites. Allogeneic bone grafts are used for nonunion treatment in some cases [21, 22] . However, successful treatment of nonunion rarely consists Fig. 1 In vivo monitoring of femoral fracture healing in the WP9QY peptide (W9) group compared to the phosphate-buffered saline (PBS) group from day 14 (2W) to day 56 (8W) . Representative in vivo X-ray radiographs of femoral fracture calluses in rats of the W9 group and the PBS group (n = 7/group). Radiographs from days 14, 28, 42, and 56 post fracture are from the same animal from either the W9 group or the PBS group. W weeks Fig. 2 Radiographic and histological evidence of fracture healing. a Fracture healing rate in the W9 and PBS groups. In the PBS group, only one of seven animals showed bridging callus formation, whereas in the W9 group four of seven demonstrated bridging callus formation. b Radiographic score of fracture healing at weeks 2, 4, 6, and 8. The radiographic score of fracture healing at week 8 assessed by Qi classification [1] was significantly higher in the W9 group compared to the PBS group (n = 7/group) (*P ≤ 0.05) of only one method or surgical treatment. The literature describes several options, such as low-intensity pulsed ultrasound (LIPUS) [23, 24] and enhancement of bone formation with recombinant bone morphogenetic protein (rBMP) treatment [25] . LIPUS has been shown to be a less invasive treatment for nonunion by enhancing bone formation [26, 27] . It speeds the healing of fresh fractures and is also effective in the treatment of established nonunions showed that callus volume was significantly higher in the W9 group than in the PBS group (n = 7 group) (*P ≤ 0.05) Fig. 4 Histological evaluation after staining with toluidine blue demonstrated enhanced endochondral ossification consisting of numerous chondrocytes and newly formed trabecular bone at week 4 (4W), bridging callus formation at week 6 (6W), and complete union at week 8 (8W) in the W9 group. In contrast, in the PBS group, although thick callus formation was observed at week 4, the healing process stopped by week 6, and ultimately the callus was absorbed at week 8. co cortical bone. a ×4; b ×10 [28] . However, the success of LIPUS treatment is not always guaranteed [29] , and treatments with rBMP or gene therapy require a huge amount of recombinant protein or vectors such as adenovirus, respectively. Therefore, a new approach is required for nonunion treatment.
In this study, radiographs of fractures in the W9 group showed promotion of callus formation and bridging bone formation, which led to a high bone union rate and radiographic score. Although only poor callus formation was observed in the area of cauterized periosteum in the PBS group, good callus formation was evident in the W9 group. The hyperplasia of the callus was good in the W9 group, but three of seven cases did not achieve bone union. These three cases were in such condition that further bone formation could not be expected even if we waited more than 8 weeks because a fibrous tissue intervened around a callus. In the bone morphometric results, it was expected that there would be a large amount of callus formed around the fracture area, because W9 inhibits osteoclastogenesis and bone resorption, but no significant difference in TV between the two groups was observed at 8 weeks. In fact, the numbers of TRAP-positive cells around the fracture site were significantly decreased. One reason for this may be that the remodeling processes had already occurred in the W9 group, so the total volume of the callus did not differ significantly between the groups at 8 weeks postoperatively. This result suggests that suppression of bone resorption by W9 did not overcome a major obstacle to remodeling and union of the fracture. In addition, because the BV/TV of the W9 group was significantly higher than that in the PBS group, W9 is likely to promote mineralization of the callus. This finding is supported by the significantly greater number of osteoblasts around the fracture site and the higher levels of and PBS groups. a TRAP-positive cell number was analyzed in a 1600 µm (height) × 2800 µm (width) area centered in the middle of the fracture callus. b The W9 group showed significantly decreased numbers of osteoclasts at 4, 6, and 8 weeks after fracture compared to the PBS group (n = 7/group) (*P ≤ 0.05, **P ≤ 0.01, respectively). ×10
Fig. 6
Quantitative analysis of osteoblast numbers in the W9 and PBS groups with Villanueva bone staining at 4 weeks after fracture. a Osteoblast numbers were analyzed in a 1600 µm (height) × 2800 µm (width) area centered in the middle of the fracture callus. b The W9 group exhibited a significantly higher osteoclast number at 4 weeks after fracture compared to the PBS group (n = 4/group). ×10 expression of bone anabolic factors within the callus in the W9 group.
Takasaki et al. [7] revealed that the W9 peptide has a unique property. W9 peptide inhibits osteoclast differentiation as a result of connecting to RANKL expressed on osteoblasts and inducing conformational changes of RANK. Furthermore, this peptide increases trabecular bone mineral density (BMD) via inhibition of osteoclastogenesis in the bone loss model of wild-type and TNF-receptor-deficient mice that underwent ovariectomy or were given a lowcalcium diet [8] . Moreover, W9 administered to mice three times per day for 5 days caused an increase of cortical BMD in the femur [9] . In vitro studies revealed that W9 peptide accelerates bone formation by stimulating production of autocrine factors such as BMPs, IGF, and CTGF, which promote osteoblast differentiation, and p38 and smad1/5/8 signaling pathways, which are involved in W9-induced osteoblastogenesis [9] . The results of the present study are consistent with these studies. Decreased numbers of TRAPpositive cells around the callus in the W9 group reflect the W9-induced inhibition of osteoclastogenesis. Moreover, higher BV/TV, osteoblast number, and expression of bone anabolic factors in callus is in accord with W9-induced osteoblastogenesis. Ultimately, not only suppression of bone resorption, but also accelerated osteoblastogenesis and mineralization of the callus, were the key to the promotion of bone union in the W9 group. All the mechanisms responsible for these effects are still unknown, and further examination will be necessary to shed light on the most suitable dosage timing, period, and dose.
Because the bone fracture healing process is complicated, the detailed mechanism underlying the accelerated bone union in the W9 group is still unknown. Elucidation of the coupling mechanism between osteoclasts and osteoblasts is indispensable to understand the mechanism of action of W9. Bone remodeling has been a major research focus for many years, as reflected by the current drugs used clinically [30] . However, the most remarkable feature of bone remodeling is probably the subtle coordination between osteoclasts and osteoblasts [31, 32] . The question of why osteoblasts are recruited exactly where and when osteoclasts have removed bone matrix has prompted much research in recent years, as indicated by the number of reviews on the coupling mechanism between osteoclast and osteoblast activities [32] [33] [34] [35] [36] . Because W9 does not exist in the living body, the existence of a so-far-unknown molecule or molecules that signal on the RANKL side is suggested. Such a device acting on the coupling mechanism may become clear by continued study of W9. Fig. 7 Gene expression of intrinsic osteogenesis-promoting cytokines at 2 weeks postoperatively. The expression levels of CTGF, Col1A1, osteocalcin, BMP4, and ALP1 in the callus of the peri-fracture site were significantly higher in the W9 group compared with the PBS group (n = 6/group) (*P ≤ 0.05). CTGF connective tissue growth factor, Col1A1 Collagen 1A1, OC osteocalcin, BMP4 bone morphogenetic protein 4, IGF1 insulin-like growth factor 1, F-mod fibromodulin, ALP1 alkaline phosphatase 1
Limitation
Because this is the first report about local injection of W9 into the fracture site, there is no report about the effective as well as safe dosage, concentration, and timing of the W9 injection. In the present study, the concentration of W9 (1 mg in 100 µl) was determined by the subcutaneous model of a previous study [9] . Thus, we believe that more detailed examination of the injection dosage, concentration, and timing of W9 is necessary. Subsequently, there are no considerations for the systematic effects of W9 local injection. Not only serum levels of bone metabolic markers, but also harmful side effects, should be checked. Moreover, when the W9 is actually used clinically, intravenous administration is the most versatile method. So, it is essential to examine the most effective protocol of vein injection for fracture treatment, and whether harmful side effects appear.
Conclusion
Our study is the first to evaluate the efficacy of W9 peptide by local injection at the fracture site. Local administration of W9 can promote bone maturation from callus and is considered to contribute to fracture healing. W9 has a unique effect on the coupling mechanism between osteoclasts and osteoblasts, which promote bone formation while working to suppress bone resorption. W9 could be a promising option for treatment of fractures in the clinical setting.
